# Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder

> **NCT04982796** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Portland VA Research Foundation, Inc** · enrollment: 30 (estimated)

## Conditions studied

- Amphetamine-Related Disorders

## Interventions

- **DRUG:** Psilocybin
- **BEHAVIORAL:** Treatment-as-usual

## Key facts

- **NCT ID:** NCT04982796
- **Lead sponsor:** Portland VA Research Foundation, Inc
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-07
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04982796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04982796, "Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04982796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*